The agreement will enable the two companies to combine a BioInvent therapeutic antibody with InNexus’ SuperAntibody Technology.
The SuperAntibody Technology has been developed to improve the potency of existing antibody products.
Under the agreement the companies will perform collaborative R&D aimed at a single target. The agreement also contains terms for future drug development including commercialization. Financial terms of the transaction were not disclosed.
“The impact of such a demonstration is to not only produce a more effective drug candidate but to also use less drug, a key to the drug’s cost of goods and profit,” said Jeff Morhet, president and CEO of BioInvent.
InNexus is headquartered in Arizona on the campus of The Mayo Clinic and has its own in-house development facilities.